Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542009 · ClinicalTrials.gov registry record · Phase 2
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
A Phase 2 study of Weight Management and Treatment Of Obesity, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT00542009: Completed Phase 2 study of Weight Management and Treatment Of Obesity, sponsored by Pfizer.
NCT00542009 is a Phase 2 study of Weight Management and Treatment Of Obesity that has completed, run by Pfizer. The registered enrollment target is 252 participants, below the 837-participant average among 8 other Weight Management trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00542009, a Phase 2 study of Weight Management and Treatment Of Obesity, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CE-326,597 100 mg QD
- DRUG CE-326,597 50 mg QD
- DRUG CE-326,597 25 mg QD
- DRUG CE-326,597 5mg QD
Study Locations (20)
California
- Pfizer Investigational Site - Fresno
- Pfizer Investigational Site - National City
- Pfizer Investigational Site - San Diego
Florida
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Ocala
- Pfizer Investigational Site - West Palm Beach
Georgia
- Pfizer Investigational Site - Atlanta
- Pfizer Investigational Site - Conyers
Illinois
- Pfizer Investigational Site - Chicago
- Pfizer Investigational Site - Chicago
Minnesota
- Pfizer Investigational Site - Chaska
- Pfizer Investigational Site - Minneapolis
Nevada
- Pfizer Investigational Site - Henderson
- Pfizer Investigational Site - Las Vegas
Arizona
- Pfizer Investigational Site - Phoenix
Hawaii
- Pfizer Investigational Site - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
What the finished NCT00542009 record still lists
NCT00542009 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, below the 837-participant average among 8 other Weight Management trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Weight Management appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT00542009 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00542009 about?
NCT00542009 is a clinical study titled "A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight". Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes
What is the current status of trial NCT00542009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2007-12. Estimated completion is 2008-11.
What conditions does trial NCT00542009 study?
This clinical trial studies the following conditions: Weight Management, Treatment Of Obesity.
What interventions are being tested in trial NCT00542009?
The interventions under investigation include: Placebo (DRUG), CE-326,597 100 mg QD (DRUG), CE-326,597 50 mg QD (DRUG), CE-326,597 25 mg QD (DRUG), CE-326,597 5mg QD (DRUG).
Who is sponsoring clinical trial NCT00542009?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00542009 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00542009's enrollment target sits among peer trials
252 2nd of 8 the highest of 8 other Weight Management trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Management trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GV101 in Healthy Obese Participants
COMPLETED · Phase 2
-
Weight Loss Management in Endometrial Cancer Survivors
RECRUITING
-
Advancing Biopsychosocial Care Training Initiative
RECRUITING · NA
-
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
RECRUITING · NA
-
Weight Management After Cancer for Survivors in Rural Communities
RECRUITING · NA
-
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia